Skip to Main Content

Paper Details

Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.
Drug Saf
18
2018
Human, PCSK9, R46L, R46L variant, cholesterol, human, hypercholesterolemia, low-density lipoprotein cholesterol, neural tube defects, patients, serine, serine protease proprotein convertase subtilisin/kexin type 9, spina bifida
Author NameAffiliation
Rebecca N JeromeVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center
Jill M PulleyVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center
Dan M RodenVanderbilt University Medical Center
Jana K Shirey-RiceVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center
Lisa BastaracheVanderbilt University School of Medicine
Lisa BastaracheVanderbilt University School of Medicine
Gordon R BernardVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center
Gordon R BernardVanderbilt University Medical Center
Joshua C DennyVanderbilt University School of Medicine
  • 1 - 9

Datasets

Release 1.2